Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial-Reference-Cited by-同舟云学术

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial

Published:2021-09-11 Issue:1 Volume:115 Page:33-42
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Nakamae Hirohisa^ORCID,Yamamoto Masahide,Sakaida Emiko,Kanda Yoshinobu,Ohmine Ken,Ono Takaaki,Matsumura Itaru,Ishikawa Maho,Aoki Makoto,Maki Akio,Shibayama Hirohiko

Funder

Novartis Pharma KK

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-021-03216-5.pdf

Reference26 articles.

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.

2. Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12(1):39.

3. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology. Chronic Myeloid Leukemia V3.2021. 2021.

4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–6.

5. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28–39.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upregulation of miR-155 induces cell cycle arrest and apoptosis in chronic myeloid leukemia;Journal of Birjand University of Medical Sciences;2024-06-01

2. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia;International Journal of Hematology;2024-05-15

3. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group;International Journal of Hematology;2024-04-08

4. Advances in the Treatment of Chronic Myeloid Leukemia;Recent Patents on Anti-Cancer Drug Discovery;2024-02

5. Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia;Internal Medicine;2024